Calcineurin inhibitors—common drugs that prevent organ rejection after transplantation—may raise uric acid levels in transplant patients, according to a 2026 systematic review of 36 studies. High uric acid occurred in 30-80% of transplant patients taking these drugs, with cyclosporin showing higher rates (51-61%) than tacrolimus (36-42%). However, researchers couldn’t draw definitive conclusions due to study quality variations and conflicting evidence.
Organ transplant patients take special drugs called calcineurin inhibitors to prevent their bodies from rejecting the new organ. However, researchers wanted to know if these drugs might cause high uric acid levels, which could increase heart disease risk. After reviewing 36 studies, scientists found that these drugs may indeed raise uric acid in transplant patients, but the evidence isn’t strong enough to say for certain. One drug (cyclosporin) appeared to cause higher uric acid levels than another (tacrolimus), though more research is needed to confirm this.
Key Statistics
A 2026 systematic review of 36 studies found that high uric acid levels occurred in 30-80% of organ transplant patients taking calcineurin inhibitors, with significant variation depending on the specific drug used.
According to a 2026 systematic review analyzing transplant drug research, cyclosporin was associated with high uric acid in 51-61% of patients compared to tacrolimus in 36-42% of patients, though researchers noted conflicting evidence across studies.
A 2026 systematic review examining 36 studies on transplant medications found that only 10 studies specifically focused on measuring uric acid control, indicating this potential drug side effect hasn’t been thoroughly investigated.
In a 2026 systematic review of 36 studies on transplant drugs and uric acid, 28 studies focused on kidney transplant patients while only 8 examined other organ transplants, leaving significant gaps in knowledge about non-kidney recipients.
The Quick Take
- What they studied: Whether two common transplant rejection-prevention drugs (cyclosporin and tacrolimus) cause high uric acid levels in organ transplant patients
- Who participated: A systematic review analyzing 36 published studies involving organ transplant patients, primarily kidney transplant recipients, with studies ranging across different countries and time periods
- Key finding: Between 30-80% of transplant patients taking calcineurin inhibitors developed high uric acid levels, with cyclosporin showing higher rates (51-61%) compared to tacrolimus (36-42%)
- What it means for you: If you’ve received an organ transplant and take these drugs, your doctor should monitor your uric acid levels regularly. However, the connection isn’t definitive enough to change treatment decisions without medical guidance—talk to your transplant team about your individual risk
The Research Details
Researchers conducted a systematic review, which means they searched medical databases for all published studies on this topic and carefully analyzed them together. They looked through two major medical databases (MEDLINE and Embase) using specific search terms combining transplant drugs with uric acid measurements. They found 639 potentially relevant studies and carefully selected 36 that met their quality standards.
Of the 36 studies included, most (28 studies) focused on kidney transplant patients, while only 8 looked at other organ transplants like heart, liver, or lung. The researchers then organized these studies into two groups: 20 studies compared calcineurin inhibitors to other transplant drugs, and 15 studies directly compared cyclosporin versus tacrolimus.
The researchers evaluated each study’s quality using a standard checklist called the Critical Appraisal Skills Programme. This helps readers understand how reliable each study’s findings are. They found that most studies had low to moderate quality, meaning the evidence wasn’t as strong as it could be.
This research approach matters because transplant patients are already at higher risk for heart disease, and high uric acid levels could add to that risk. By reviewing all available studies together, researchers can see the bigger picture rather than relying on just one study. However, because the studies used different methods and measured things differently, it’s hard to draw firm conclusions—which is exactly what this review discovered.
The overall quality of evidence was low to moderate, meaning readers should be cautious about applying these findings too broadly. Only 10 of the 36 studies specifically focused on measuring uric acid control. The studies varied significantly in their methods, patient populations, and how they measured uric acid, making direct comparisons difficult. This variation is why the researchers couldn’t reach definitive conclusions despite reviewing 36 studies.
What the Results Show
The review found that high uric acid levels were common in transplant patients taking calcineurin inhibitors, occurring in 30-80% of patients depending on the study. This wide range shows how differently studies measured and reported this problem. When researchers compared the two main drugs, cyclosporin appeared to cause higher uric acid levels (51-61% of patients) compared to tacrolimus (36-42% of patients).
However, the researchers emphasized that these findings should be interpreted carefully. The studies they reviewed had different designs, followed patients for different lengths of time, and measured uric acid in different ways. Some studies looked at kidney transplant patients only, while others included different organ types. These differences made it difficult to draw strong conclusions.
The review also noted that many other factors besides the transplant drugs could affect uric acid levels, including diet, genetics, kidney function, and other medications patients were taking. The studies didn’t always account for these confounding factors, which could have influenced the results.
The review found that most research focused on kidney transplant patients (28 of 36 studies), leaving gaps in knowledge about other organ transplants. Only 10 studies specifically designed their research to measure uric acid control, while others measured it as a side observation. This suggests that uric acid control hasn’t been a major focus of transplant research, even though it could affect patient health. The researchers also noted that very few studies compared the long-term effects of these drugs on uric acid levels.
According to Gram Research analysis, this systematic review brings together conflicting evidence from previous studies. Some earlier research suggested calcineurin inhibitors definitely raise uric acid, while other studies found no clear connection. This review shows why those disagreements existed: studies used different methods and patient populations. The finding that cyclosporin may cause more uric acid problems than tacrolimus aligns with some previous research but contradicts other studies, indicating this comparison needs more high-quality research.
The biggest limitation is that the included studies had low to moderate quality overall, meaning their findings may not be completely reliable. The studies were very different from each other in how they were designed and conducted, making it impossible to combine their results statistically. Most studies focused only on kidney transplant patients, so findings may not apply to heart, liver, or lung transplant recipients. Many studies didn’t measure or report uric acid levels as their main focus, so important information may have been missed. Finally, the studies didn’t always account for other factors that affect uric acid, such as diet, weight, alcohol use, and other medications.
The Bottom Line
Transplant patients taking calcineurin inhibitors should have their uric acid levels checked regularly as part of routine monitoring (moderate confidence). If high uric acid develops, discuss with your transplant team whether medication adjustments or dietary changes might help (moderate confidence). Don’t stop or change your transplant rejection-prevention drugs without medical guidance, as preventing organ rejection is critical (high confidence). If you develop symptoms of gout or have a family history of uric acid problems, inform your transplant team (moderate confidence).
This research matters most for people who have received solid organ transplants and take cyclosporin or tacrolimus. It’s particularly relevant for kidney transplant patients, since most research focused on this group. Transplant doctors and nurses should use this information to guide monitoring decisions. People considering organ transplantation should discuss uric acid risk with their transplant team. This research is less immediately relevant for people who haven’t had transplants or take different immunosuppressive drugs.
High uric acid levels can develop within weeks to months of starting these drugs, so monitoring should begin soon after transplantation. Benefits from dietary changes or medication adjustments typically appear within 4-8 weeks. Long-term monitoring is important because uric acid problems may persist as long as patients take these drugs. If gout develops, it may take several weeks of treatment to resolve symptoms.
Frequently Asked Questions
Do transplant rejection drugs cause high uric acid?
Calcineurin inhibitors (cyclosporin and tacrolimus) may raise uric acid levels in transplant patients, occurring in 30-80% of cases. However, research shows conflicting evidence, so the connection isn’t definitive. Your transplant team should monitor your uric acid regularly.
Which transplant drug is better for uric acid control?
Tacrolimus appears to cause lower uric acid levels (36-42% of patients) compared to cyclosporin (51-61%), according to a 2026 systematic review. However, conflicting study findings mean this comparison isn’t certain, and drug choice depends on many other medical factors.
How often should transplant patients get uric acid tested?
While this review doesn’t specify testing frequency, standard transplant care typically includes uric acid monitoring every 3-6 months. Ask your transplant team about the right schedule for your situation, especially if you have risk factors for high uric acid.
Can I lower my uric acid if I’m taking transplant drugs?
Yes, dietary changes like reducing red meat, organ meats, and alcohol may help lower uric acid. If levels remain high, your doctor can prescribe uric acid-lowering medications. Never stop or change your transplant rejection drugs without medical guidance.
Does high uric acid from transplant drugs increase heart disease risk?
High uric acid is associated with increased cardiovascular risk, which is why monitoring matters for transplant patients who already have elevated heart disease risk. Managing uric acid levels through diet and medication may help reduce this additional risk.
Want to Apply This Research?
- Log uric acid test results every 3-6 months with the date and value. Track any gout symptoms (joint pain, swelling, redness) and when they occur. Note any dietary changes or new medications that might affect uric acid levels.
- Set reminders for scheduled uric acid blood tests. Keep a food diary noting high-purine foods (red meat, organ meats, certain seafood, alcohol) and any correlation with uric acid spikes. Share uric acid trends with your transplant team during appointments.
- Create a chart showing uric acid levels over time to identify trends. Flag results that are higher than your baseline or outside normal range. Use the app to prepare questions for your transplant doctor about uric acid management at each visit.
This article summarizes research findings and is not medical advice. Organ transplant patients should not change their medications or monitoring based on this information without consulting their transplant team. Calcineurin inhibitors are critical for preventing organ rejection, and any decisions about these drugs must be made with your transplant physician. If you have concerns about uric acid levels or gout symptoms, discuss them with your healthcare provider at your next appointment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.